Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Colorcon
Mallinckrodt
Merck
McKinsey

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LUM001

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for LUM001?

LUM001 is an investigational drug.

There have been 12 clinical trials for LUM001. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Cholestasis, Syndrome, and Liver Diseases. The leading clinical trial sponsors are Shire, Lumena Pharmaceuticals, Inc., and Childhood Liver Disease Research and Education Network.

There are eight US patents protecting this investigational drug and one hundred and twenty-four international patents.

Recent Clinical Trials for LUM001
TitleSponsorPhase
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyMirum Pharmaceuticals, Inc.Phase 2
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)Mirum Pharmaceuticals, Inc.Phase 3
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid ExcretionShirePhase 1

See all LUM001 clinical trials

Clinical Trial Summary for LUM001

Top disease conditions for LUM001
Top clinical trial sponsors for LUM001

See all LUM001 clinical trials

US Patents for LUM001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LUM001   Start Trial Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL)   Start Trial
LUM001   Start Trial Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL)   Start Trial
LUM001   Start Trial Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL)   Start Trial
LUM001   Start Trial Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides   Start Trial
LUM001   Start Trial Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle & Co. (Skokie, IL)   Start Trial
LUM001   Start Trial Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake G.D. Searle, LLC (St. Louis, MO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LUM001

Drugname Country Document Number Estimated Expiration Related US Patent
LUM001 Argentina 019880 2018-07-02   Start Trial
LUM001 Austria 199718 2014-09-13   Start Trial
LUM001 Austria 234829 2014-09-13   Start Trial
LUM001 Austria 256122 2014-09-13   Start Trial
LUM001 Austria 303378 2014-09-13   Start Trial
LUM001 Australia 1721399 2014-09-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Express Scripts
Medtronic
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.